These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 28892049)
21. The mucin MUC4 and its membrane partner ErbB2 regulate biological properties of human CAPAN-2 pancreatic cancer cells via different signalling pathways. Jonckheere N; Skrypek N; Merlin J; Dessein AF; Dumont P; Leteurtre E; Harris A; Desseyn JL; Susini C; Frénois F; Van Seuningen I PLoS One; 2012; 7(2):e32232. PubMed ID: 22393391 [TBL] [Abstract][Full Text] [Related]
22. MUC4 enhances gemcitabine resistance and malignant behaviour in pancreatic cancer cells expressing cancer-associated short O-glycans. Sagar S; Leiphrakpam PD; Thomas D; McAndrews KL; Caffrey TC; Swanson BJ; Clausen H; Wandall HH; Hollingsworth MA; Radhakrishnan P Cancer Lett; 2021 Apr; 503():91-102. PubMed ID: 33485947 [TBL] [Abstract][Full Text] [Related]
23. Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice. Wang X; Wang JP; Rao XM; Price JE; Zhou HS; Lachman LB Breast Cancer Res; 2005; 7(5):R580-8. PubMed ID: 16168101 [TBL] [Abstract][Full Text] [Related]
24. Muc4/sialomucin complex, an intramembrane modulator of ErbB2/HER2/Neu, potentiates primary tumor growth and suppresses apoptosis in a xenotransplanted tumor. Komatsu M; Jepson S; Arango ME; Carothers Carraway CA; Carraway KL Oncogene; 2001 Jan; 20(4):461-70. PubMed ID: 11313977 [TBL] [Abstract][Full Text] [Related]
25. Interaction of Muc4 and ErbB2 in a transgenic mouse model of gallbladder carcinoma: potential pathobiological implications. Miyahara N; Shoda J; Kawamoto T; Ishida H; Ueda T; Akimoto Y; Kawakami H; Irimura T Oncol Rep; 2014 Nov; 32(5):1796-802. PubMed ID: 25174601 [TBL] [Abstract][Full Text] [Related]
26. Core needle biopsy of breast cancer tumors increases distant metastases in a mouse model. Mathenge EG; Dean CA; Clements D; Vaghar-Kashani A; Photopoulos S; Coyle KM; Giacomantonio M; Malueth B; Nunokawa A; Jordan J; Lewis JD; Gujar SA; Marcato P; Lee PW; Giacomantonio CA Neoplasia; 2014 Nov; 16(11):950-60. PubMed ID: 25425969 [TBL] [Abstract][Full Text] [Related]
27. A moderate elevation of circulating levels of IGF-I does not alter ErbB2 induced mammary tumorigenesis. Dearth RK; Kuiatse I; Wang YF; Liao L; Hilsenbeck SG; Brown PH; Xu J; Lee AV BMC Cancer; 2011 Aug; 11():377. PubMed ID: 21867536 [TBL] [Abstract][Full Text] [Related]
28. Loss of periostin/OSF-2 in ErbB2/Neu-driven tumors results in androgen receptor-positive molecular apocrine-like tumors with reduced Notch1 activity. Sriram R; Lo V; Pryce B; Antonova L; Mears AJ; Daneshmand M; McKay B; Conway SJ; Muller WJ; Sabourin LA Breast Cancer Res; 2015 Jan; 17(1):7. PubMed ID: 25592291 [TBL] [Abstract][Full Text] [Related]
38. Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis. Singh AP; Moniaux N; Chauhan SC; Meza JL; Batra SK Cancer Res; 2004 Jan; 64(2):622-30. PubMed ID: 14744777 [TBL] [Abstract][Full Text] [Related]
39. Metastasis is an early event in mouse mammary carcinomas and is associated with cells bearing stem cell markers. Weng D; Penzner JH; Song B; Koido S; Calderwood SK; Gong J Breast Cancer Res; 2012 Jan; 14(1):R18. PubMed ID: 22277639 [TBL] [Abstract][Full Text] [Related]
40. Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors. Landis MD; Seachrist DD; Abdul-Karim FW; Keri RA Oncogene; 2006 Jun; 25(23):3325-34. PubMed ID: 16434967 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]